Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT02200991

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02200991
Other papers using this trial's data
  • Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study) Diabetes, obesity & metabolism, 2017-09 DOI, PubMed 28345162, PMC5573929 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02200991. Randomized; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LIXISENATIDE AVE0010
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Insulin glargine HOE901
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02200991
Content hash
e7694687bba350a3151da37cff4660b31927fee70518bb77547ecf412b9808c4